These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17506717)

  • 1. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists.
    Moulder JE; Fish BL; Cohen EP
    Curr Pharm Des; 2007; 13(13):1317-25. PubMed ID: 17506717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy.
    Moulder JE; Fish BL; Cohen EP
    Curr Pharm Des; 2003; 9(9):737-49. PubMed ID: 12570791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy.
    Moulder JE; Fish BL; Cohen EP
    Int J Radiat Biol; 1998 Apr; 73(4):415-21. PubMed ID: 9587080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors.
    Moulder JE; Cohen EP; Fish BL
    Int J Radiat Biol; 2014 Sep; 90(9):762-8. PubMed ID: 24991882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy.
    Cohen EP; Fish BL; Moulder JE
    Curr Drug Targets; 2010 Nov; 11(11):1423-9. PubMed ID: 20583975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists.
    Molteni A; Ward WF; Ts'ao CH; Taylor J; Small W; Brizio-Molteni L; Veno PA
    Curr Pharm Des; 2003; 9(9):751-61. PubMed ID: 12570792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist.
    Moulder JE; Fish BL; Cohen EP
    Radiother Oncol; 1998 Mar; 46(3):307-15. PubMed ID: 9572624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker.
    Molteni A; Moulder JE; Cohen EF; Ward WF; Fish BL; Taylor JM; Wolfe LF; Brizio-Molteni L; Veno P
    Int J Radiat Biol; 2000 Apr; 76(4):523-32. PubMed ID: 10815633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary sodium modification and experimental radiation nephropathy.
    Moulder JE; Fish BL; Cohen EP
    Int J Radiat Biol; 2002 Oct; 78(10):903-11. PubMed ID: 12465655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief pharmacological intervention in experimental radiation nephropathy.
    Moulder JE; Fish BL; Cohen EP
    Radiat Res; 1998 Nov; 150(5):535-41. PubMed ID: 9806595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
    Stergiou GS; Skeva II
    Curr Top Med Chem; 2004; 4(4):473-81. PubMed ID: 14965313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P; Plouin PF
    Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor antagonists in the prevention of radiation nephropathy.
    Moulder JE; Fish BL; Cohen EP; Bonsib SM
    Radiat Res; 1996 Jul; 146(1):106-10. PubMed ID: 8677292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy.
    Mogyorosi A; Sonkodi S
    Diabetes Metab Res Rev; 1999; 15(1):55-8. PubMed ID: 10398547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model development and use of ACE inhibitors for preclinical mitigation of radiation-induced injury to multiple organs.
    Medhora M; Gao F; Wu Q; Molthen RC; Jacobs ER; Moulder JE; Fish BL
    Radiat Res; 2014 Nov; 182(5):545-55. PubMed ID: 25361399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.